Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood

The purpose of this study is to see if see if adding the specific combination of donors can result in acceptable levels of survival without evidence of disease.

Trial Details

NCT ID
NCT06904482
Phase
PHASE2
Sponsor
Case Comprehensive Cancer Center
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Haplo-Identical / Cord Blood Transplant
Locations (sample)
  • Cleveland, Ohio, United States|41.4995,-81.69541

Key Eligibility Criteria

  • Participants with the following hematologic malignancies:
  • Acute myelogenous leukemia (AML): High-risk AML including:
  • Antecedent hematological disease (e.g., myelodysplasia (MDS))
  • Treatment-related

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →